Castle Biosciences CSTL 深 滬
等待開盤 10-31 09:30:00 美东时间
24.21
+0.470
+1.98%
華盛通- 最 高24.43
- 今 開23.73
- 成交量 19.67万股
- 最 低 23.73
- 昨 收 23.74
- 總市值 7.02亿
- 52周最高 34.64
- 市盈率 靜 38.82
- 換手率 0.68%
- 52周最低 14.59
- 委 比 -92.07%
- 總股本 2900.83万
- 歷史最高 107.69
- 量 比 1.00
- 振 幅 2.95%
- 歷史最低 9.2601
- 每 手 1
- 風險率 4.84%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多New Data at American College of Gastroenterology Annual Meeting Show TissueCypher® Provides Actionable Risk Insights that Influence Clinical Management and Prompt Risk-Aligned Intervention in Barrett’s Esophagus
Castle Biosciences' TissueCypher Barrett’s Esophagus test received a Presidential Poster Award for its high-quality, novel research at the 2025 ACG Annual Meeting. The test provides risk insights beyond pathology alone, supporting personalized clinical management to enable earlier intervention for higher-risk patients and reduce unnecessary procedures for lower-risk patients. Three posters highlighting the test's performance in assessing progress...
10-26 19:05
DecisionDx-Melanoma Validated Across Cutaneous Melanoma Subtypes In 13,560 Patients With Results To Be Presented By Castle Biosciences At Dermatology Conference
This new histological subtype data confirms DecisionDx-Melanoma's clinical value across the spectrum of melanomaCastle Biosciences will also present validation data on its atopic dermatitis pipeline test
10-24 16:16
New Analysis of 13,560 Patients Demonstrates DecisionDx®-Melanoma Stratifies Risk Across Histological Subtypes; Findings to be Presented at Fall Clinical Dermatology Conference
Castle Biosciences presented new data at the 25th Annual Fall Clinical Dermatology Conference, highlighting the clinical value of its DecisionDx-Melanoma test across histological subtypes of melanoma, supported by a study of 13,560 patients. The test demonstrates significant risk stratification, showing improved melanoma-specific survival rates for lower-risk patients versus higher-risk groups. Additionally, the company shared validation data on ...
10-24 08:05
Castle Biosciences Honored with a Greater Pittsburgh Top Workplaces 2025 Award
Castle Biosciences, Inc. has been recognized as a Greater Pittsburgh Top Workplace 2025 by The Pittsburgh Post-Gazette, based on anonymous employee feedback. The company ranked third in its size bracket within the healthcare industry and has received eight other workplace accolades this year. Derek Maetzold, CEO, credited the achievement to employees' contributions to improving patient care. Castle Biosciences specializes in innovative diagnostic...
09-23 11:00
Castle Biosciences Named One of Newsweek’s America’s Greatest Companies 2025
Castle Biosciences Inc. has been named to Newsweek's inaugural 2025 America's Greatest Companies list, recognizing its strong performance in financial strength, workforce dedication, innovation, and environmental sustainability. The company, which specializes in innovative diagnostic tests to improve patient care, was praised for its commitment to putting people first in all aspects of its business.
09-17 11:00
Castle Biosciences Study Finds 15% of Barrett's Esophagus Patients Face Higher Cancer Risk Than Pathology Suggests
Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced that new data demonstrating the personalized risk stratification provided by its
09-09 19:19
New Data at American Foregut Society's 2025 Annual Meeting Demonstrates TissueCypher® Can Detect High-Risk Barrett’s Esophagus Patients Not Identified by Pathology to Support Improved Care Decisions
<p>TissueCypher的最新研究显示，15%的非发育不良性Barrett食管(NDBE)患者疾病进展风险与低级别发育不良(LGD)相似或更高，而现行指南建议对LGD患者进行及时干预以防止疾病进展。这项研究将在2025年美国腑 GCC 会上以主题演讲形式分享。研究结果表明，TissueCypher能够提供比传统病理更精准的风险评估，识别出易被忽视的高风险患者，从而帮助医生制定个性化随访和治疗策略，降低患者发展为食管腺癌的风险。</p>
09-09 11:00
New Evidence Published Supporting Use of DecisionDx®-SCC Test in Guiding and Improving Treatment Pathway Decisions in NCCN High-Risk Cutaneous Squamous Cell Carcinoma
Two new studies highlight DecisionDx-SCC's superior performance in predicting local recurrence and metastasis risks for high-risk cutaneous squamous cell carcinoma (SCC) patients, surpassing current staging systems. The test also aligns with clinician treatment thresholds for adjuvant radiation therapy and surveillance imaging. Among 414 high-risk SCC patients, DecisionDx-SCC significantly stratified risk, showing progressively lower survival rat...
08-25 11:00
Castle Biosciences to Participate in Upcoming Investor Conferences
Castle Biosciences, Inc. (Nasdaq: CSTL) announced that its executive management will present a company overview at Baird’s 2025 Global Healthcare Conference on September 10, 2025, at 10:15 a.m. Eastern time. The presentation will be available via live audio webcast on the company’s website and replay afterward. Additionally, the company will host one-on-one investor meetings at the Wells Fargo 20th Annual Healthcare Conference on September 4, 202...
08-21 11:00
Castle Biosciences Updates Bylaws for Improved Governance
The latest update is out from Castle Biosciences ( ($CSTL) ). On August 5, 2025...
08-09 04:41
